Psychemedics Corp. Files Proxy Statement Supplement

TL;DR

Psychemedics filed a proxy update, no fee. Shareholders get more info.

AI Summary

Psychemedics Corp. filed a Definitive Additional Materials filing (DEFA14A) on November 18, 2024, supplementing its proxy statement. This filing concerns the company's proxy materials and does not involve a fee, as indicated by the 'No fee required' checkbox. The filing is an amendment to a previous filing, as noted by 'Amendment No. 1'.

Why It Matters

This filing provides updated information to shareholders regarding the company's proxy materials, which is crucial for their participation in corporate governance decisions.

Risk Assessment

Risk Level: low — This is a routine administrative filing related to proxy statements and does not contain new financial or operational information that would typically indicate high risk.

Key Players & Entities

• PSYCHEMEDICS CORP (company) — Registrant
• 0001171843-24-006411 (filing_id) — Accession Number
• 20241118 (date) — Filing Date

FAQ

Filing Documents

• defa14a_112524.htm (DEFA14A) — 10KB
• header.jpg (GRAPHIC) — 7KB
• 0001171843-24-006411.txt ( ) — 21KB

From the Filing

14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington , D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant Filed by a party other than the Registrant Check the appropriate box: Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to §240.14a-12 PSYCHEMEDICS CORPORATION (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): No fee required Fee paid previously with preliminary materials Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Proxy Statement Supplement This proxy statement supplement (this “Supplement”) updates the definitive proxy statement on Schedule 14A (the “Proxy Statement”) of Psychemedics Corporation (the “Company”) filed with the Securities and Exchange Commission on October 18, 2024 and made available to stockholders in connection with the Company’s annual meeting of stockholders to be held on November 25, 2024 (the “Proxy Statement”). Except as specifically described in this Supplement, all information set forth in the Proxy Statement continues to apply and this Supplement does not modify, amend or supplement the Proxy Statement. The Proxy Statement contains important additional information. This Supplement should be read in conjunction with the Proxy Statement. Subsequent to the mailing of the Proxy Statement to the Company’s stockholders, the New York Stock Exchange (the “NYSE”) notified the Company of its determination that Proposal 7 in the Proxy Statement regarding the adjournment of the Annual Meeting (the “Adjournment Proposal”) is a discretionary or “routine” matter under NYSE rules. The “routine” designation permits brokers to exercise discretionary voting authority with respect to such proposal. Accordingly, if you do not instruct your broker on how to vote your shares of the Company’s common stock on the Adjournment Proposal, your broker will be permitted to vote your shares in its discretion on the Adjournment Proposal. Because the NYSE has determined the Adjournment Proposal is a “routine” matter, the Company does not expect any “broker non-votes” in connection therewith. November 18, 2024

View Full Filing

View this DEFA14A filing on SEC EDGAR